miR-593-3p Promotes Proliferation and Invasion in Prostate Cancer Cells by Targeting ADIPOR1

References

• Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–2542. doi:10.1001/jama.2017.7248
   PubMed Web of Science ®Google Scholar
• Annala M, Vandekerkhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8(4):444–457. doi:10.1158/2159-8290.CD-17-0937
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75(2):285–293. doi:10.1016/j.eururo.2018.07.035
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79(1):150–158. doi:10.1016/j.eururo.2020.08.011
   PubMed Web of Science ®Google Scholar
• Wang G, Zhao D, Spring DJ, et al. Genetics and biology of prostate cancer. Genes Dev. 2018;32:1105–1140. doi:10.1101/gad.315739.118
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. doi:10.1016/j.cell.2009.01.002
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222. doi:10.1038/nrd.2016.246
   PubMed Web of Science ®Google Scholar
• Ivey KN, Srivastava D. MicroRNAs as regulators of differentiation and cell fate decisions. Cell Stem Cell. 2010;7(1):0–41. doi:10.1016/j.stem.2010.06.012
   Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610. doi:10.1038/nrg2843
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524.
   PubMed Web of Science ®Google Scholar
• Kanwal R, Plaga AR, Liu X, et al. MicroRNAs in prostate cancer: functional role as biomarkers. Cancer Lett. 2017;407:9–20. doi:10.1016/j.canlet.2017.08.011
   PubMed Web of Science ®Google Scholar
• Fabris L, Ceder Y, Chinnaiyan AM, et al. The potential of microRNAs as prostate cancer biomarkers. Eur Urol. 2016;70(2):312–322. doi:10.1016/j.eururo.2015.12.054
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun Y, Wang P, et al. Exploration of the molecular mechanism of prostate cancer based on mRNA and miRNA expression profiles. Onco Targets Ther. 2017;10:3225–3232. doi:10.2147/OTT.S135764
   PubMed Web of Science ®Google Scholar
• Dong L, Hong H, Chen X, et al. LINC02163 regulates growth and epithelial-to-mesenchymal transition phenotype via miR-593-3p/FOXK1 axis in gastric cancer cells. Artif Cells Nanomed Biotechnol. 2018;46(sup2):607–615. doi:10.1080/21691401.2018.1464462
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhou H, Yuan K, et al. Overexpression of hsa_circ_0136666 predicts poor prognosis and initiates osteosarcoma tumorigenesis through miR-593-3p/ZEB2 pathway. Aging. 2020;12(11):10488–10496. doi:10.18632/aging.103273
   PubMedGoogle Scholar
• Han W, Wang L, Zhang L, et al. Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593–3p/CCND2 and miR-653–5p/TIAM1 pathways in non-small cell lung cancer. Biochem Bioph Res Co. 2019;510(3):462–466. doi:10.1016/j.bbrc.2019.01.131
   PubMed Web of Science ®Google Scholar
• Hata T, Mizuma M, Masuda K, et al. MicroRNA-593-3p expression in peritoneal lavage fluid as a prognostic marker for pancreatic cancer patients undergoing staging laparoscopy. Ann Surg Oncol. 2021;28(4):2235–2245. doi:10.1245/s10434-020-09440-3
   PubMed Web of Science ®Google Scholar
• Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature. 2010;464(7293):1313–1319. doi:10.1038/nature08991
   PubMed Web of Science ®Google Scholar
• Sun LY, Li XJ, Sun YM, et al. LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1. Mol Cancer. 2018;17(1):127. doi:10.1186/s12943-018-0879-9
   PubMedGoogle Scholar
• Liu X, Chen J, Zhang J. AdipoR1-mediated miR-3908 inhibits glioblastoma tumorigenicity through downregulation of STAT2 associated with the AMPK/SIRT1 pathway. Oncol Rep. 2017;37(6):3387–3396. doi:10.3892/or.2017.5589
   PubMed Web of Science ®Google Scholar
• Hwang MS, Yu N, Stinson SY, et al. miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One. 2013;8(6):e66502. doi:10.1371/journal.pone.0066502
   PubMed Web of Science ®Google Scholar
• Li T, Li M, Hu S, et al. MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1. Int J Boil Macromol. 2017;103:1054–1061. doi:10.1016/j.ijbiomac.2017.05.108
   PubMed Web of Science ®Google Scholar
• Karnati HK, Panigrahi MK, Li Y, et al. Adiponectin as a potential therapeutic target for prostate cancer. Curr Pharm Design. 2017;23(28). doi:10.2174/1381612823666170208123553
   PubMed Web of Science ®Google Scholar
• Gao Q, Yao X, Zheng J. MiR-323 inhibits prostate cancer vascularization through adiponectin receptor. Cell Physiol Biochem. 2015;36(4):1491–1498. doi:10.1159/000430313
   PubMedGoogle Scholar
• Parashar D, Geethadevi A, Aure MR, et al. miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell Rep. 2019;29(13):4389–4440. doi:10.1016/j.celrep.2019.11.085
   PubMed Web of Science ®Google Scholar
• Chen C, Gupta P, Parashar D, et al. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Oncogene. 2020;39(14):2921–2933. doi:10.1038/s41388-020-1194-7
   PubMed Web of Science ®Google Scholar
• Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121–135. doi:10.1038/nrm.2017.95
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84. doi:10.1038/s41580-018-0080-4
   PubMed Web of Science ®Google Scholar
• Huang Q, Ma B, Su Y, et al. miR-197-3p represses the proliferation of prostate cancer by regulating the VDAC1/AKT/β-catenin signaling axis. Int J Biol Sci. 2020;16(8):1417–1426. doi:10.7150/ijbs.42019
   PubMed Web of Science ®Google Scholar
• Beermann J, Piccoli M, Viereck J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–1325. doi:10.1152/physrev.00041.2015
   PubMed Web of Science ®Google Scholar
• Yuan H, Han Y, Wang X, et al. SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways. Cancer Cell. 2020;38(3):350–365. doi:10.1016/j.ccell.2020.05.022
   PubMed Web of Science ®Google Scholar
• Kim SM, Nguyen TT, Ravi A, et al. PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discov. 2018;8(7):866–883. doi:10.1158/2159-8290.CD-17-1215
   PubMed Web of Science ®Google Scholar
• Zadra G, Priolo C, Patnaik A, et al. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res. 2010;16(13):3322–3328. doi:10.1158/1078-0432.CCR-09-1955
   PubMed Web of Science ®Google Scholar
• Song Y, Zeng S, Zheng G, et al. FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis. Oncogene. 2021;40(4):777–790. doi:10.1038/s41388-020-01562-y
   PubMed Web of Science ®Google Scholar
• Mak P, Leav I, Pursell B, et al. ERβ impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for gleason grading. Cancer Cell. 2010;17(4):319–332. doi:10.1016/j.ccr.2010.02.030
   PubMed Web of Science ®Google Scholar
• Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev. 2002;82(3):673–700. doi:10.1152/physrev.00005.2002
   PubMed Web of Science ®Google Scholar
• Crooke ST, Wang S, Vickers TA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017;35(3):230–237. doi:10.1038/nbt.3779
   PubMed Web of Science ®Google Scholar
• Shen M, Xie S, Rowicki M, et al. Therapeutic targeting of metadherin suppresses colorectal and lung cancer progression and metastasis. Cancer Res. 2021;81(4):1014–1025. doi:10.1158/0008-5472.CAN-20-1876
   PubMed Web of Science ®Google Scholar